Highlights

In brief

The Mfsap1 enzyme, produced by the skin yeast Malassezia furfur, is significantly more active in patients with atopic dermatitis and seborrheic dermatitis than in healthy individuals, indicating its potential role in these skin conditions.

© Shutterstock

Breakaway yeasts instigate the itch

22 Feb 2024

Researchers discover a protein-cutting enzyme that may be responsible for inflammatory skin conditions triggered by yeast species.

We often think of our skin’s microbiome as predominantly bacterial. Surprisingly, yeast such as Malassezia also thrive on warm, moist, greasy and nutrient-rich human skin. While typically harmless, Malassezia can sometimes flip from friend to foe, triggering dermatological conditions from dandruff to dermatitis.

“In individuals with healthy skin, the skin barrier is usually intact, which allows the skin to function properly as a protective barrier defending against the external environment,” said Thomas Dawson, Deputy Executive Director at the A*STAR Skin Research Labs (A*SRL).

Dawson explained that when this barrier is compromised, Malassezia can infiltrate into deeper layers of skin where they secrete many compounds including protein-digesting enzymes called proteases, which lead to itchy, inflammatory flare-ups.

Historically, researchers have encountered hurdles in trying to connect the dots between protease genes and the exacerbation of skin conditions—the yeast is difficult to genetically modify and grow in the lab for experimental analyses. Using a novel approach, Dawson teamed up with collaborators from the National University of Singapore; National Skin Centre, Singapore; University of California San Diego, USA; and the University of Zürich, Switzerland to study the gene expression profiles of Malassezia furfur, a more experimentally accessible model organism for studying the yeast’s impact on skin health.

First, the team took skin samples from patients with atopic or seborrheic dermatitis, alongside healthy volunteers. Gene expression analyses revealed that individuals with dermatitis showed a marked uptick in the expression of MGSAP1, a protease gene.

The researchers then disabled a similar yeast gene called MFSAP1 in M. furfur and observed changes in the way the yeast cells stick together and grow on lab-grown human skin. They found that the absence of MFSAP1 in a mouse model resulted in significantly less skin inflammation, as indicated by reduced swelling and fewer inflammatory cells, compared to the wild-type M. furfur. This confirmed the team’s hypothesis that the Mfsap1 protease is involved in the host inflammatory response.

“Mfsap1-mediated modifications of the cell surface and the external environment can enable the fungal cells to become more hydrophobic, contributing to a shift from free-floating to adherent cells,” explained Joleen Goh, the first author of the study.

Goh added that these newly gained insights explain how the yeast interacts with the skin environment, which can enable targeted treatments for inflammatory skin conditions.

“Future treatment of Malassezia-associated conditions can be coupled with enzyme inhibitors and antimycotics in controlling infections to improve clinical outcomes,” Dawson and Goh suggested, adding that their group plans to study how M. furfur attaches to medical devices like catheters, which is particularly dangerous for high-risk patients such as new-borns and the immunocompromised receiving lipid emulsions.

The A*STAR-affiliated researchers contributing to this research are from the A*STAR Skin Research Labs (A*SRL), Bioinformatics Institute (BII) and the Institute of Molecular and Cell Biology (IMCB).

Want to stay up to date with breakthroughs from A*STAR? Follow us on Twitter and LinkedIn!

References

Goh, J.P.Z., Ruchti, F., Poh, S.E., Koh, W.L.C., Tan, K.Y., et al. The human pathobiont Malassezia furfur secreted protease Mfsap1 regulates cell dispersal and exacerbates skin inflammation. Proceedings of the National Academy of Sciences USA 119 (49), e2212533119 (2022). | article

About the Researcher

View articles

Thomas Dawson

Deputy Executive Director

A*STAR Skin Research Labs (A*STAR SRL)
Thomas Dawson earned his PhD in pharmacology from the University of North Carolina in 1994. He then joined the Duke University Medical Center from 1994-1996 as a Pediatric Clinical Medical Genetics Fellow. From 1998-2015 he worked in Procter & Gamble’s Beauty Technology Division, before joining A*STAR’s Institute of Medical Biology (IMB) to develop and lead translational programs in hair and scalp biology. In 2018, Dawson moved to the Skin Research Institute of Singapore (SRIS) and the A*STAR Skin Research Institute (A*SRL), where he is currently the Deputy Executive Director. Dawson has over 30 years of research experience in end-to-end drug discovery, 30 granted patents, multiple products in the market, and a unique background in skin, hair and microbiome research.

This article was made for A*STAR Research by Wildtype Media Group